Filing identity and reporting period
Important mismatch: The supplied filing is Senesco Technologies, Inc.’s Form 10-Q for the quarter and six months ended December 31, 2012—not an Eloxx Pharmaceuticals, Inc. filing. The filing describes Senesco as a development-stage biotechnology company. Its interim financial statements are unaudited.
Business context
Senesco develops gene-regulation technology for human therapeutics and agricultural applications. Its lead drug candidate, SNS01-T, was being studied in a Phase 1b/2a trial for relapsed or refractory multiple myeloma, with potential application to other B-cell cancers. The company also licensed its technology to agricultural partners.
Financial results and position
| Metric | Six months ended Dec. 31, 2012 | Comparable 2011 period |
|---|---|---|
| Revenue | $0 | $200,000 |
| Operating expenses | $2,546,200 | $2,936,283 |
| Net loss | $3,355,339 | $2,566,554 |
| Net cash used in operating activities | $1,201,869 | $2,297,885 |
For the three months ended December 31, 2012, revenue was zero and net loss was $1,269,885, compared with $200,000 revenue and a $1,527,571 net loss in the year-earlier quarter. The filing reports no gross margin; with no current-period revenue, a revenue margin is not meaningful.
At December 31, 2012, cash was $640,125, total current assets were $1,935,673, and current liabilities were $3,752,785, resulting in a working-capital deficit of $1,817,112. Total liabilities were $3,882,812 and stockholders’ equity was $1,580,975. The company had a $2,199,108 line-of-credit balance, unchanged from June 30, 2012; the stated annual rate was the broker rate plus 2% (5.75% at quarter-end). Cash fell by $1,361,200 during the six-month period.
There is no meaningful operating margin given the absence of revenue and continuing operating losses. The filing reports an accumulated development-stage deficit of $71,443,789.
Material changes and unusual items
- Six-month net loss increased $788,785, or 30.7%, year over year, despite lower operating expenses. The increase reflected no current-period milestone revenue and a $785,171 loss on extinguishment of debt, among other items.
- Operating expenses declined 13.3% to $2.55 million. Research and development fell 20.3% to $1.10 million, while general and administrative expense fell 7.0% to $1.44 million. Management attributed lower R&D largely to reduced agricultural and formulation costs; human therapeutics accounted for 97% of six-month R&D spending.
- The company exchanged warrants for common shares, recorded the $785,171 extinguishment loss, and reclassified $164,205 of warrant liability to equity. The remaining warrant liability was $30,299 at December 31, versus $238,796 at June 30.
- Preferred-stock conversions and warrant exchanges substantially increased common shares outstanding. A January 2013 offering issued 30 million shares and warrants to purchase another 30 million shares.
Outlook, liquidity, and risks
Management said December cash plus proceeds from the January 2013 offering would fund operations through July 2013; additional capital would be needed to fund operations through at least December 31, 2013. The January offering raised $3.0 million gross. The filing gives approximately $2.9 million net after estimated offering expenses and separately identifies $600,000 for investor-relations purposes; another passage describes approximately $2.3 million after that allocation. The company said it expected continued losses for several years and could not predict when, if ever, it would become profitable.
The filing identifies substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, negative operating cash flows, and the need for further financing. If additional funds are unavailable, Senesco may delay or reduce development, license rights to third parties, seek a strategic transaction or sale, cease operations, or file for bankruptcy.
On the clinical front, management reported that the first SNS01-T trial cohort was completed: the candidate was described as safe and well tolerated, with stable disease in two of three evaluable patients; the second cohort was underway. These early results do not establish efficacy. Key risks include clinical and regulatory failure, reliance on outside research partners and licensees, uncertain commercialization and milestone revenue, patent and intellectual-property challenges, dilution, and a limited trading market. The filing also states that the company was no longer listed on NYSE MKT and could no longer use its ATM sales agreement. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Most important facts to verify
- Confirm the issuer and reporting period: this filing is for Senesco Technologies, Inc., not Eloxx Pharmaceuticals, Inc.
- Verify the January 2013 offering’s net proceeds and the treatment of the $600,000 investor-relations allocation.
- Assess near-term funding needs against the stated July 2013 cash runway and the going-concern disclosure.
- Review the $2.199 million line of credit, its demand-note terms, and the collateral support provided by a director.
- Track SNS01-T trial progress and safety data, while distinguishing preliminary findings from demonstrated clinical benefit.
- Evaluate dilution from issued shares, preferred-stock conversion rights, and outstanding or newly issued warrants.